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MHC = major histocompatibilty complex.
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Gram-positive infections account for up to 50% of cases
of severe sepsis in the modern intensive care unit. The
complex processes by which Gram-positive organisms
cause sepsis are poorly understood by comparison with
Gram-negative sepsis. Much interest is currently focused
on the role of certain protein exotoxins synthesized by
Staphylococcus aureus and Streptococcus pyogenes,
which share the immunological property of being super-
antigens. Superantigens are characterized by the ability to
bypass normal major histocompatibility complex (MHC)-
restricted, intracellular, antigen processing and presenta-
tion. Through direct binding to the MHC class II molecule
and the T cell receptor, at sites away from those involved
in conventional antigen binding, superantigens activate up
to 50% of the whole T cell repertoire rather than the 1%
fraction stimulated by conventional antigens. The precise
biological advantage of superantigen production to these
organisms is uncertain. Such toxins are, however, believed
to have a role in causation of two classic superantigen-
mediated diseases, staphylococcal and streptococcal
toxic shock syndromes, that kill 5000 Americans per
annum. They may also contribute to the pathogenesis of
other forms of Gram-positive shock.
In addition to intensive care support and antimicrobial
therapy, various adjunctive treatments for toxic shock syn-
drome have been evaluated both in vitro and in clinical
trials (Table 1). Nevertheless, the treatment of toxic shock
syndrome, like that of conventional forms of sepsis,
remains suboptimal and the disease is still associated with
mortality in the region of 50% and associated with consid-
erable morbidity.
Arad  et al reported a novel approach to treatment of
superantigen-mediated disease [1]. They identified a
dodecapeptide that is highly conserved among different
bacterial superantigens and lies in a region of the super-
antigen molecule away from sites involved with either
MHC class II or T cell receptor interaction. Several modi-
fied forms of this peptide acted as antagonists to a range
of bacterial superantigens against which they were tested
in vitro. One dodecapeptide, which was a particularly
effective antagonist, was administered to mice challenged
with bolus doses of bacterial superantigen. The peptide
was protective both before and after superantigen chal-
lenge. Arad et al speculate that the mechanism of inhibi-
tion may involve co-stimulatory pathways of T cell
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activation. Interestingly, protection against subsequent
challenges, at 3-weekly intervals, improved with each chal-
lenge. This improved protection correlated with antibody
production against the whole challenge superantigen,
while antibody against the dodecapeptide was not
detected. This finding is in keeping with the previously
observed correlation between lack of antibody against
streptococcal pyrogenic exotoxin A and development of
invasive S. pyogenes infection [2]. One consequence of
the cytokine storm induced by superantigens may be to
disrupt the development of antibody-mediated immunity.
By switching off superantigenicity, the dodecapeptide may
be allowing normal antibody production to occur.
Although the prospect of drugs to switch off superanti-
genicity is exciting, there have been many false dawns in
the field of sepsis research. Animal studies of superanti-
gen-mediated human disease have well recognized limita-
tions. All laboratory animals are intrinsically resistant to the
effects of bacterial superantigens. The mouse model,
while being one of the best established systems for study-
ing toxic shock, requires far higher doses of superantigen
than are needed to induce shock in humans, and prior
‘sensitization’ of the animal with the hepatotoxin D-galac-
tosamine. We have recently demonstrated, in a mouse
model of invasive streptococcal infection, that other prop-
erties of these toxins may be more important than their
superantigenicity and, paradoxically, such effects may in
fact be advantageous to the host [3]. Furthermore, admin-
istration of bolus doses of superantigen probably does not
reflect the pattern of toxin production in clinical cases.
Certain findings of the report by Arad et al are at odds
with our current understanding of bacterial superantigens.
The study found that animals protected from one super-
antigen in an initial challenge were cross-protected
against different superantigens in subsequent challenges.
This effect was observed for toxins as dissimilar as staphy-
lococcal exotoxin B and toxic shock syndrome toxin 1,
which have only 6% sequence homology. This is hard to
understand in terms of neutralizing antibody since no
cross-reactivity between toxic shock syndrome toxin 1 and
other superantigens has been demonstrated in serological
or neutralization assays.
The paper by Arad et al is the first published report of
superantigen antagonist peptides. Encouragingly, at least
one other group is making progress in the same area, and
have demonstrated a protective effect not only against
bolus doses of superantigen, but also in a model of co-
challenge with endotoxin [4]. Further studies to address
the mode of action of these peptides, particularly in super-
antigen-sensitive animal models (Sriskandan et al, manu-
script submitted), are necessary before speculation about
clinical trials is warranted.
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Specific approaches to treatment of toxic shock syndromes
Strategy Experimental data Reference
Clindamycin Toxin production is switched off at sub-bacteriocidal concentrations of antibiotic.  [5,6]
Clindamycin use is associated with reduced mortality compared with historical controls
Intravenous immunoglobulin Immunoglobulin neutralizes streptococcal pyrogenic exotoxins in vitro. IgA and IgM  [7–9]
supplemented preparations may be superior to pure IgG preparations. Adjunctive therapy 
with intravenous immunoglobulin is associated with improved survival compared with 
` historical controls
Toxoids of pyrogenic exotoxins Non-superantigenic mutants of SPEA and SPEC protect rabbits from a toxin challenge [10,11]
SPEA, Streptococcal pyrogenic exotoxin A; SPEC, streptococcal pyrogenic exotoxin C.
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